Abstract
The approach described herewith is an attempt to use antibodies directed towards tumor-associated antigens or other polymers or macromolecules, as carriers for cytotoxic anti-cancer agents in order to improve the effectiveness of cancer chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnon, R., 1979, Anti-tumor antibodies as carriers for anti-cancer drugs, in:“Tumor-associated antigens and their specific immune response, F. Spreafico and R. Arnon, eds., Academic Press, New York.
Bergman, Y., and Haimovich, J., 1977, Characterization of a carcino- gen-induced murine B lymphocyte cell line of C3H/eB origin, Eur. J. Immunol. 7: 413.
Bernstein, A., Hurwitz, E., Maron, R., Arnon, R., Sela, M., and Wilchek, M., 1978, Higher antitumor efficacy of daunomycin when linked to dextran: in vivo and in vitro studies, J. Natl. Cancer Inst. 60: 379.
Blythman, H.E., Casellas, P., Gros, O., Gros, P., Jansen, F.K., Paolucci, F., Pau, B., and Vidal, H., 1981, Immunotoxins: hybrid molecules of monoclonal antibodies and a toxin subunit specifically kill tumor cells, Nature 290: 145.
Davies, D.A.L., and O’Neil, G.J., 1973, In vivo and in vitro effects of tumor specific antibodies with chlorambucil, Br. J. Cancer 28: Suppl. I, 285.
Davies, D.A.L. and O’Neil, G.J., 1974, Protection of mice against syngeneic lymphomata, II, Collaboration between drugs and antibodies, Br. J. Cancer 30: 305.
De-Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., and van Hoof, F., 1974, Lysosomotropic agents, Biochem. Pharmacol. 23: 2495.
Ehrlich, P., 1906, “Collected Studies on Immunity”, Vol II,John Wiley, New York.
Eshhar, Z., Hurwitz, E., and Hadas, E., 1980, Production of hybridomas secreting monoclonal antibodies against components of normal and malignant cells, in: “New Developments With Human and Veterinary Vaccines”, Alan R. Liss Inc., New York.
Flechner, I., 1973, The cure and concomitant immunization of mice bearing Ehrlich ascites tumors by treatment with an antibodyalkylating agent complex, Eur. J. Cancer 9: 741.
Frei, E., 1972, Prospects for cancer chemotherapy, Cancer 30: 1656.
Ghose, T., Norvell, S.T., Guclu, A., Cameron, D., Bodurtha, A., and Mac-Donald, A.S., 1972, Immunochemotherapy of cancer with chlorambucyl carrying antibody, Br. Med. J. 3: 495.
Gillagoda, A.C., Mannuel, C., Tan, C.T.C., Wollner, V., Steinberg, S.S., and Murphy, M.L., The cardiotoxicity of adriamycin and daunomycin in children, Cancer 37: 1070.
Gilliland, D.G., Stepelewski, Z., Collier, R.J., Mitchell, K.F., Chang, T.H., and Koprowski, H., 1981, Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells, Proc. Natl. Acad. Sci. U.S.A. 77: 4539.
Gregoriadis, G., 1977, Targeting of drugs, Nature 265: 407. Gronwall, A., and Ingelman, B., 1944, Untersuchungen uber dextran and sein verhalten bei parenteraler Zufuhr, Acta Physiol. Scand, 7: 97.
Haran-Ghera, N., and Peled, A., 1973, Thymus and bone marrow derived lymphatic leukemia in mice, Nature 241: 396.
Hurwitz, E., Maron, R., Arnon, R., and Sela, M., 1975, The covalent binding of daunomycin and adriamycin to antibodies with retention of both drug and antibody activities, Cancer Res. 35: 1175.
Hurwitz, E., Maron R., Arnon, R., and Sela, M., 1976, Fab dimers of anti-tumor immunoglobulins as covalent carriers of daunomycin, Cancer Biochem. Bioyhys. 1: 197.
Hurwitz, E., Maron, R., Arnon, R., Wilchek, M., and Sela, M., 1978a, Daunomycin-immunoglobulin conjugates, uptake and activity in vitro, Eur. J. Cancer 14: 1213.
Hurwitz, E., Maron, R., Bernstein, A., Wilchek, M., Sela, M., and Arnon, R., 1978b, The effect in vivo of chemotherapuetic drug antibody conjugates in two murine experimental tumor systems, Int. J. Cancer 21: 747.
Hurwitz, E., Schechter, B., Arnon, R., and Sela, M., 1979, Binding of anti-tumor immunoglobulins and their daunomycin conjugates to the tumor and its metastases, In vitro and in vivo studies with Lewis Lung Carcinoma, Int. J. Cancer 24: 461.
Hurwitz, E., Wilchek, M., and Pita, J., 1980, Soluble molecules as carriers for daunorubicin, J. Applied Biochem. 2: 25.
Hurwitz, E., Kashi, R., and Wilchek, M., 1981, Platinum couplexed anti-tumor immunoglobulins specifically inhibit DNA synthesis of tumor cells, submitted.
Isliker, H., Cerottini, J.C., Jaton, J.-C., and Magnenat, G., 1969, Specific and non-specific fixation of plasma proteins in tumors, in: “Chemotherapy of Cancer”, Elsevier, Amsterdam.
Katchalski, E., and Sela, M., 1958, Synthesis and chemical properties of poly-a-amino acids, Adv. Prot. Chem. 8: 243.
Kitao, T., and Hattori, K., 1977, Concanavalin A as a carrier of daunomycin, Nature 265: 81.
Klein, E., and Klein, G., 1964, Antigenic properties of lymphoma induced by Moloney agent, J. Natl. Cancer Inst. 32: 547.
Kohler, G., and Milstein, C., 1976, Derivation of specific antibody producing tissue culture and tumor lines by cell fusion, J. Immunol. 6: 511.
Krolick, K.A., Villemez, C., Isakson, P., Uhr, J.W., And Vitetta,E.S., 1980, Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin, Proc. Natl. Acad. Sci. USA. 77: 5419.
Levi-Schaffer, F., Bernstein, A., Meshorer, A., and Arnon, R., Reduced toxicity of daunomycin by conjugation to dextran, Cancer Treatment Reports, in press.
Levy, R., Hurwitz, R., Maron, R., Arnon, R., and Sela, M., 1975, The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies, Cancer Res. 35: 1182.
Magnenat, R., Schidler, R., and Isliker, H., 1969, Transport d’agents cytostatiques par le proteines plasmatiques. III. Activite’antitumorale in vitro de conjugues cytostatiqueazoproteines, Eur. J. Cancer 5: 33.
Mathe; G., Tran, B.L., and Bernard, J., 1958, Essai sur la leucemie 1210 de la souris d’une combinaison par diazotazion d’amethopterine et de y-globulines de hamsters porteurs de cette leucemie par hetergreffe, Compt. Rend. 246: 1626.
Molteni, E.L., and Scrollini, F., 1977, Méthode,pour prolonger l’action des medicaments par la formation de composes macromoleculaires, Eur. J. Med. Chem. 9: 618.
Nisonoff, A., Wissler, F.C., Lippman, L.N., and Woernley, D.L., 1960, Separation of univalent fragments from bivalent rabbit antibody molecule by reduction of disulfide bonds, Arch. Biochem. Biophys. 89: 230.
O’Bryan, R.M., Luce, J.K., Talky, R.W., Gottlieb, J.K., Baker, L.H., and Bonadonna, G., 1973, Phase II evaluation of adriamycin in human neoplasia, Cancer 32: 1.
O’Neill, G.J., 1979, The use of antibodies as drug carriers, in: “Drug Carrier in Biology and Medicine”, G. Gregoriadis, ed., Academic Press, London.
Potter, M., and Robertson, C.L., 1960, Development of plasma-cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin-oil adjuvant, heat-killed staphylococcus mixtures, J. Natl. Cancer Inst. 25: 847.
Rubens, R.D., and Dulbecco, R., 1974, Augmentation of cytotoxic drug action by antibodies directed at cell surface, Nature 248: 81.
Segerling, M., Ohanian, S.H., and Borsos, T., 1974, Effect of metabolic inhibitors on killing of tumor cells by antibody and complement, J. Natl. Cancer Inst. 53: 1411.
Sequira, K., and Stock, C.C., 1955, Studies in a tumor spectrum. III. The effects of phosphoramides on the growth of a variety of mouse and rat tumors, Cancer Res. 15: 38.
Szekerke, M., Wade, R., and Whisson, M.E., 1967, Some serum protein nitrogen mustard complexes with high chemotherapeutic selectivity, Nature, 215: 1303.
Szekerke, M., Wade, R., and Whisson, M.E., 1972, The use of macromolecules as carriers of cytotoxic groups. I. Conjugates of nitrogen mustards with proteins, polypeptidyl proteins and polypeptides, Neoplasma 19: 179.
Trouet, A., Deprez-de Campeneere, D., and De Duve, C., 1972, Chemotherapy through lysosomes with a DNA-daunorubicin complex, Nature 239: 110.
Trouet, A., Deprez-’de Campeneere, D., De Smedt-Molengreaux, M., Attasi, G., 1974, Experimental leukemia chemotherapy with a “lysosomotropic” adriamycin-DNA complex, Eur. J. Cancer 10: 405.
Varga, J.M., Asato, N., Lande, S., and Lerner, A.B., 1977, Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells, Nature 267: 56.
Youle, R.J., and Neville, Jr., D.M., 1980, Anti-thy-1,2 monoclonal antibody linked to ricin is a potent cell type specific toxin, Proc. Natl. Acad. Sci. USA 77: 5843.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Plenum Press, New York
About this chapter
Cite this chapter
Arnon, R. (1982). Antibodies and Dextran as Anti-Tumour Drug Carriers. In: Gregoriadis, G., Senior, J., Trouet, A. (eds) Targeting of Drugs. NATO Advanced Study Institutes Series, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4241-0_3
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4241-0_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4243-4
Online ISBN: 978-1-4684-4241-0
eBook Packages: Springer Book Archive